Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Puts Velcade Second For First-Line Multiple Myeloma; Janssen To Appeal

This article was originally published in The Pink Sheet Daily

Executive Summary

Janssen's Velcade and Celgene's thalidomide both recommended as first-line multiple myeloma therapies, but thalidomide is more cost-effective, says NICE's final appraisal determination.

You may also be interested in...



NICE Wants More Evidence To Clear Janssen’s Velcade For Multiple Myeloma

The British HTA NICE wants more clinical and cost-effectiveness data on Janssen’s Velcade in combination therapy before clearing it for battle with thalidomide for multiple myeloma.

Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time

Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.

Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time

Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.

Topics

UsernamePublicRestriction

Register

PS071095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel